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Ibrutinib impairs the phagocytosis of 
rituximab-coated leukemic cells from chronic 
lymphocytic leukemia patients by human
macrophages
Ibrutinib is an oral irreversible inhibitor of the bruton
tyrosine kinase (Btk) which has shown promising efficacy
and excellent tolerability in patients with chronic lympho-
cytic leukemia (CLL) and other B-cell malignancies.1
Ibrutinib inhibits BCR signaling, impairs chemokine-medi-
ated adhesion and migration, and induces moderate levels
of apoptosis on CLL cells.2,3 It also reduces TCR down-
stream activation on Th2 cells by targeting another kinase,
the interleukin-2–inducible kinase (Itk).4 The combination
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Figure 1. Ibrutinib impairs rituximab (Rx)-
coated CLL cells phagocytosis by human
macrophages. Human macrophages
were obtained by culturing monocytes
from healthy donors’ peripheral blood (A-
C and E-H) or from chronic lymphocytic
leukemia patients’ peripheral blood (D)
in RPMI 1640 medium supplemented
with 10% FCS and with GM-CSF (100
ng/mL) for five days. Purified CLL cells
were labeled with 1 µM of CFSE
(Invitrogen, Life Technologies, Carlsbad,
CA, USA) and then coated or not with 50
µg/mL of rituximab (Roche Diagnostics
GmbH, Mannheim, Germany) in RPMI
1640 medium for 30 min at 4°C. (A) For
the phagocytosis assay macrophages
were cultured for 30 min in 48-well
plates in RPMI 1640 medium supple-
mented with 10% FCS in the presence of
0.5 µM of Ibrutinib (MedKoo Biosciences
Inc, Chapel Hill, NC, USA) or the vehicle of
the drug, DMSO (Control). Then, uncoated
CFSE-labeled CLL cells or rituximab-coat-
ed CFSE-labeled CLL (Rx) were added to
the culture. The phagocytosis was evalu-
ated after 1, 2, and 3 h of culture when
macrophages were trypsinized and ana-
lyzed by using a FACScan flow cytometer
(BD Immunocytometry Systems, San
Jose, CA, USA). The graph shows the per-
centage of macrophages (determined by
morphology in the FSC-H and SSC-H dot
plot) that have taken up CLL cells as the
percentage of CFSE+ macrophages
(n=4). (B and C) The phagocytosis assay
was performed in the presence of DMSO
(control) or ibrutinib at 0.5 µM and 5 µM,
with uncoated CFSE-labeled CLL cells or
coated with rituximab (B) (P=0.0001,
Kruskal-Wallis test followed by Dunn's
multiple comparison test *P=0.01 to
0.05 and ***P<0.001) or campath
(Cam) (C) (P=0.0467, Kruskal-Wallis test
followed by Dunn's Multiple Comparison
Test *P<0.05). The percentage of CFSE+
macrophages was analyzed by flow
cytometry after 1 h of culture. 
(D) The same phagocytosis assay was performed with macrophages derived from CLL patients, dot plots showing FSC-H vs. CFSE of a rep-
resentative experiment and the percentages of CFSE+ macrophages are shown. (E) The phagocytosis assay was performed as previously
described and macrophages were stained with anti-CD14-PE mAb after trypsinization. Then, cells were centrifuged onto cytospin slides
and coverslips were mounted on the microscope slide using Fluoromount G. Immunofluorescence images were acquired with a FluoView
FV1000 confocal microscope (Olympus, Tokio, Japan) using a Plapon 60 X 1.42 NA oil immersion objective and images were analyzed
using the Olympus FV10-ASW software. The phagocytosis was evaluated by a double-blind method, with a separate operator counting at
least 200 cells for each experimental condition, and calculating the percentage of macrophages that engulfed at least one tumor target
cell with respect to total macrophages. (Kruskal-Wallis test followed by Dunn's Multiple Comparison Test *P=0.01 to 0.05, **P=0.01 to
0.001 and ***P<0.001). (F) Images from a representative experiment are shown. Macrophages that have phagocyte CFSE+ CLL cells are
indicated with white arrows. 3X magnification from the original images are shown in the insert. (G) To analyze if Ibrutinib could modify
macrophage-binding of rituximab-coated CLL cells, macrophages were cultured with Ibrutinib for 90 min, then detached with cold PBS-
EDTA and incubated with uncoated or rituximab-coated CFSE-labeled CLL cells for 15 min at 4°C, to avoid the internalization of the cells.
Afterwards cells were washed with PBS and analyzed by flow cytometry. The graph shows the percentage of macrophages that bind
CFSE+ cells (n=5). (H) Macrophages were treated for 2 h with ibrutinib, then some of them were washed out and drug-free medium was
added to the culture (wash-out) while others were left with the drug present in the culture and the phagocytosis assay was performed as
described before (T0 without wash-out). Washed-out macrophages were then used to perform the phagocytosis assay immediately after
ibrutinib was removed (T0 wash out) or after 7 or 24 h of culture in drug-free medium (T7 h or T24 h wash out). *P<0.05, Kruskal-Wallis
test followed by the Dunn's Multiple Comparison Test.
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of ibrutinib with different targeted therapies is now being
explored. In a single arm study, the combination of ibruti-
nib and rituximab in patients with high-risk CLL was gen-
erally well-tolerated and resulted in an overall response
(OR) rate of 95% and a progression-free survival (PFS) of
78% at 18 months.5 The added effect of rituximab to the
ibrutinb therapy is being tested in a randomized trial testing
ibrutinb versus ibrutinb and rituximab (clinicaltrials.gov iden-
tifier 02007044). Given that macrophages are the most
important effector cells in the anti-CD20-therapeutic effect
in murine models,6,7 and that they probably play a key role
in human anti-CD20 therapy,8,9we asked whether ibrutinib
could interfere with the capacity of human macrophages to
mediate phagocytosis of rituximab-coated CLL cells. Our
results showed that ibrutinib impairs the phagocytosis of
rituximab-opsonized CLL cells by human macrophages.
Macrophages differentiated from healthy peripheral
blood monocytes were treated with or without ibrutinib
for 30 min and then cultured for 1, 2 or 3 h with CFSE-
labeled CLL cells or rituximab-coated CFSE-labeled CLL
cells. Cells were then trypsinized and the proportion of
macrophages that have taken up CFSE-labeled CLL cells
(CFSE+ macrophages) were scored by flow cytometry and
verified using confocal microscopy, as previously
described.10 As expected, we found that the cultures with
rituximab-coated CLL cells showed the highest percentage
of CFSE+ macrophages, which increase in a time-depen-
dent manner (Figure 1A, open circles). Ibrutinib was able to
reduce these values in all the times evaluated (Figure 1A,
solid circles). Low percentages of CFSE+ macrophages were
obtained in cultures with uncoated CLL cells, which were
not modified by ibrutinib (Figure 1A, open and solid
squares). In addition, we found that ibrutinib diminishes
the percentage of CFSE+ macrophages in the cultures with
rituximab-coated cells in a dose-dependent manner (Figure
1B), which was not associated to a decreased viability of
the macrophages (data not shown). Moreover, the inhibitory
effect of ibrutinib was not limited to rituximab since com-
parable results were obtained when campath-coated CFSE-
labeled CLL cells were employed (Figure 1C). Similar
results were found when macrophages from CLL patients
were used: mean±SE of the percentage of CFSE+
macrophages: 26.8±2.1 versus 17.3±27 versus 10.8±0.7 for
macrophages cultured with rituximab-coated CFSE-labeled
CLL cells alone, with 0.5 µM or 5 µM of ibrutinib (n=6).
Representative dot plots are shown in Figure 1D. The
results obtained by flow cytometry analysis were validated
by confocal microscopy quantifying the number of
macrophages that engulfed at least one tumor target cell
(Figure 1E). A representative experiment is shown in Figure
1F. In addition, by performing a binding assay at 4°C, we
confirmed that ibrutinib did not reduce the binding of rit-
uximab-coated CFSE-labeled CLL cells to macrophages
(Figure 1G). It should be mentioned that although ibrutinib
5 µM seems to increase the binding of CLL to
macrophages, this difference was not statistically signifi-
cant.
We next asked if macrophages could recover their phago-
cytic capacity once ibrutinib was removed from the culture.
To this aim, macrophages were treated with ibrutinib for 2
h and then either washed- or not washed-out, and imme-
diately used for the phagocytosis assay. In addition,
washed-out macrophages were cultured in ibrutinib-free
medium for 7, 24 and 48 h before performing the phagocy-
tosis assay. As shown in Figure 1H, the phagocytosis of rit-
uximab-coated CLL cells by macrophages was impaired
when ibrutinib was present (T0 without wash-out) or
immediately after ibrutinib was removed (T0 wash-out).
Interestingly when ibrutinib was washed out, macrophages
recovered their phagocytic capacity after 7 h (T 7 h wash-
out), 24 h (T 24 h wash-out) and 48 h of culture (data not
shown) in drug-free medium (Figure 1H), showing a
reversible effect on macrophages. In contrast, we con-
firmed a previous report by Honigberg et al.11 showing that
ibrutinib was able to irreversibly inhibit BCR-mediated
activation of CLL cells (data not shown). Thus, while ibruti-
nib binds to Btk in an irreversible manner on CLL cells, its
inhibitory effect on the phagocytosis of rituximab-coated
CLL cells by macrophages was reversible and needed the
continuous presence of the drug, suggesting the existence
of a reversible target, other than Btk. In line with this, ibru-
tinib was shown to inhibit other kinases11 including Hck,
Fgr, and Lyn, which were described to be involved in Fc-
mediated phagocytosis on macrophages.12 So it is possible
that ibrutinib impairment of macrophage phagocytosis
involves binding to one or more of these kinases in a
reversible manner. 
Our results are in line with those recently reported by
Kohrt et al.13 showing that ibrutinib prevented natural killer
cell-mediated cytotoxicity of antibody-coated CLL cells in
vitro. They also found that the concurrent treatment with
ibrutinib and rituximab or trastuzumab reduces the thera-
peutic efficacy of both anti-CD20 antibodies in a mouse
model, while the sequential treatment with ibrutinib and
rituximab restored its anti-lymphoma activity. Moreover,
similar results showing ibrutinib inhibition of rituximab-
dependent functions on macrophages and neutrophils
were published in this Journal while this manuscript was
under evaluation.14 Although the combination of rituximab
and ibrutinib has been shown to be active and safe in high-
risk CLL patients,5 our results and those obtained by Kohrt
et al.13 and by Da Roit et al.14 suggest that the sequential
administration of ibrutinib followed by rituximab, and not
the concurrent treatment with these agents, might enhance
their anti-tumor activity in vivo and improve CLL therapy.
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